KALV
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Chiesi Group agreed to acquire KalVista Pharmaceuticals to expand its global rare disease portfolioApr 29, 2026
- KalVista presented new data showing high patient satisfaction and evolving treatment trends with EKTERLY® (sebetralstat)Mar 2, 2026
- KalVista announced EKTERLY was included as a first-line therapy for adolescents aged 12 and older in international pediatric HAE guidelinesFeb 18, 2026
- KalVista announces approval of EKTERLY® (sebetralstat) in Japan as first oral on-demand HAE treatmentDec 22, 2025
- KalVista Pharmaceuticals to present new EKTERLY® (sebetralstat) data at 20th German Allergy CongressSep 26, 2025